Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Colorectal Cancer Metastatic 3Advanced Solid Tumors 3Neoplasm Metastasis 2Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Metastatic Gastric Adenocarcinoma 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Endometrial Neoplasms 1ESCC 1Desmoid Tumors 1Craniopharyngioma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Anal Cancer Metastatic 1Advanced/Metastatic Solid Tumors 1Adenomatous Polyposis Coli 1

Interventions

pembrolizumab 26Paclitaxel 22Oxaliplatin 20Nivolumab 16Docetaxel 16Capecitabine 16Cisplatin 15Fluorouracil 11Cyclophosphamide 11fludarabine 10S 1 (combination) 10Trastuzumab 9Irinotecan 9Carboplatin 8Leucovorin 7tislelizumab 6aldesleukin 5Ramucirumab 5Interleukin-2 5Gemcitabine 5Drug Therapy 5Bevacizumab 5sintilimab 4fludarabine phosphate 4apatinib 4Radiotherapy 4Everolimus 4regorafenib 3olaparib 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Stomach Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Emory University

Phase 1/2 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡